Literature DB >> 22506481

A novel α-conotoxin MII-sensitive nicotinic acetylcholine receptor modulates [(3) H]-GABA release in the superficial layers of the mouse superior colliculus.

Tristan D McClure-Begley1, Charles R Wageman, Sharon R Grady, Michael J Marks, J Michael McIntosh, Allan C Collins, Paul Whiteaker.   

Abstract

Mouse superficial superior colliculus (SuSC) contains dense GABAergic innervation and diverse nicotinic acetylcholine receptor subtypes. Pharmacological and genetic approaches were used to investigate the subunit compositions of nicotinic acetylcholine receptors (nAChR) expressed on mouse SuSC GABAergic terminals. [(125) I]-Epibatidine competition-binding studies revealed that the α3β2* and α6β2* nicotinic subtype-selective peptide α-conotoxin MII-blocked binding to 40 ± 5% of SuSC nAChRs. Acetylcholine-evoked [(3) H]-GABA release from SuSC crude synaptosomal preparations is calcium dependent, blocked by the voltage-sensitive calcium channel blocker, cadmium, and the nAChR antagonist mecamylamine, but is unaffected by muscarinic, glutamatergic, P2X and 5-HT3 receptor antagonists. Approximately 50% of nAChR-mediated SuSC [(3) H]-GABA release is inhibited by α-conotoxin MII. However, the highly α6β2*-subtype-selective α-conotoxin PIA did not affect [(3) H]-GABA release. Nicotinic subunit-null mutant mouse experiments revealed that ACh-stimulated SuSC [(3) H]-GABA release is entirely β2 subunit-dependent. α4 subunit deletion decreased total function by >90%, and eliminated α-conotoxin MII-resistant release. ACh-stimulated SuSC [(3) H]-GABA release was unaffected by β3, α5 or α6 nicotinic subunit deletions. Together, these data suggest that a significant proportion of mouse SuSC nicotinic agonist-evoked GABA-release is mediated by a novel, α-conotoxin MII-sensitive α3α4β2 nAChR. The remaining α-conotoxin MII-resistant, nAChR agonist-evoked SuSC GABA release appears to be mediated via α4β2* subtype nAChRs.
© 2012 The Authors. Journal of Neurochemistry © 2012 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22506481      PMCID: PMC4026281          DOI: 10.1111/j.1471-4159.2012.07759.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  39 in total

1.  125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain.

Authors:  P Whiteaker; J M McIntosh; S Luo; A C Collins; M J Marks
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

2.  Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors.

Authors:  L M Marubio; A M Gardier; S Durier; D David; R Klink; M M Arroyo-Jimenez; J M McIntosh; F Rossi; N Champtiaux; M Zoli; J-P Changeux
Journal:  Eur J Neurosci       Date:  2003-04       Impact factor: 3.386

3.  Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum.

Authors:  Michele Zoli; Milena Moretti; Alessio Zanardi; J Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

4.  Functional nicotinic acetylcholine receptors containing α6 subunits are on GABAergic neuronal boutons adherent to ventral tegmental area dopamine neurons.

Authors:  Kechun Yang; Lori Buhlman; Ghous M Khan; Robert A Nichols; Guozhang Jin; J Michael McIntosh; Paul Whiteaker; Ronald J Lukas; Jie Wu
Journal:  J Neurosci       Date:  2011-02-16       Impact factor: 6.167

5.  Excitatory and inhibitory circuitry in the superficial gray layer of the superior colliculus.

Authors:  P H Lee; M Schmidt; W C Hall
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167

6.  Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions.

Authors:  Sharon R Grady; Karen L Murphy; Jian Cao; Michael J Marks; J Michael McIntosh; Allan C Collins
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

7.  The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors.

Authors:  Changhai Cui; T K Booker; Roberta S Allen; Sharon R Grady; Paul Whiteaker; Michael J Marks; Outi Salminen; Theresa Tritto; Christopher M Butt; W R Allen; Jerry A Stitzel; J Michael McIntosh; Jim Boulter; Allan C Collins; Stephen F Heinemann
Journal:  J Neurosci       Date:  2003-12-03       Impact factor: 6.167

8.  Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice.

Authors:  Nicolas Champtiaux; Cecilia Gotti; Matilde Cordero-Erausquin; Denis J David; Cédric Przybylski; Clément Léna; Francesco Clementi; Milena Moretti; Francesco M Rossi; Nicolas Le Novère; J Michael McIntosh; Alain M Gardier; Jean-Pierre Changeux
Journal:  J Neurosci       Date:  2003-08-27       Impact factor: 6.167

9.  Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.

Authors:  Outi Salminen; Karen L Murphy; J Michael McIntosh; John Drago; Michael J Marks; Allan C Collins; Sharon R Grady
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

10.  Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors.

Authors:  J Michael McIntosh; Layla Azam; Sarah Staheli; Cheryl Dowell; Jon M Lindstrom; Alexander Kuryatov; James E Garrett; Michael J Marks; Paul Whiteaker
Journal:  Mol Pharmacol       Date:  2004-04       Impact factor: 4.436

View more
  5 in total

1.  Presynaptic GABAB autoreceptor regulation of nicotinic acetylcholine receptor mediated [(3)H]-GABA release from mouse synaptosomes.

Authors:  Tristan D McClure-Begley; Sharon R Grady; Michael J Marks; Allan C Collins; Jerry A Stitzel
Journal:  Biochem Pharmacol       Date:  2014-06-19       Impact factor: 5.858

2.  A novel α4/7-conotoxin LvIA from Conus lividus that selectively blocks α3β2 vs. α6/α3β2β3 nicotinic acetylcholine receptors.

Authors:  Sulan Luo; Dongting Zhangsun; Christina I Schroeder; Xiaopeng Zhu; Yuanyan Hu; Yong Wu; Maegan M Weltzin; Spencer Eberhard; Quentin Kaas; David J Craik; J Michael McIntosh; Paul Whiteaker
Journal:  FASEB J       Date:  2014-01-07       Impact factor: 5.191

3.  Reduced α4 subunit expression in α4+- and α4+- /β2+- nicotinic acetylcholine receptors alters α4β2 subtype up-regulation following chronic nicotine treatment.

Authors:  Milena Moretti; Francesca Fasoli; Cecilia Gotti; Michael J Marks
Journal:  Br J Pharmacol       Date:  2017-08-01       Impact factor: 8.739

4.  Pharmacologically distinct nicotinic acetylcholine receptors drive efferent-mediated excitation in calyx-bearing vestibular afferents.

Authors:  J Chris Holt; Kevin Kewin; Paivi M Jordan; Peter Cameron; Marcin Klapczynski; J Michael McIntosh; Peter A Crooks; Linda P Dwoskin; Anna Lysakowski
Journal:  J Neurosci       Date:  2015-02-25       Impact factor: 6.167

5.  TC299423, a Novel Agonist for Nicotinic Acetylcholine Receptors.

Authors:  Teagan R Wall; Brandon J Henderson; George Voren; Charles R Wageman; Purnima Deshpande; Bruce N Cohen; Sharon R Grady; Michael J Marks; Daniel Yohannes; Paul J Kenny; Merouane Bencherif; Henry A Lester
Journal:  Front Pharmacol       Date:  2017-09-26       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.